As Insulet (Nasdaq:PODD) continues to grow in its leadership position within the insulin patch pump market, other entries ...

Insulet (PODD) stock gains as UBS upgrades the company, citing its growth prospects in the Type 2 diabetes market. Read more ...

Insulet Corporation (NASDAQ: PODD), best known for its Omnipod insulin delivery system, is emerging as a compelling ...

Insulet stock rose moderately early Thursday as its insulin pump, Omnipod, delivered double-digit growth in the U.S. and ...

Q3 2025 Management View CEO Ashley McEvoy welcomed Flavia Pease as the new CFO and announced Eric Benjamin's promotion to COO and the appointment of Manoj Raghunandanan as Chief Growth Officer. McEvoy ...

Following the strong performance, Insulet raised its full-year 2025 revenue growth guidance to 28-29% in constant currency, up from its previous outlook of 24-27%. The company also increased its gross ...

Insulet reported Omnipod revenue of $699.2 million for the third quarter of 2025, up 31% over the same quarter in 2024 ...

Insulet (Nasdaq:PODD) shares rose slightly before hours today on third-quarter results that landed well ahead of the ...

Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery ...

Insulet Corporation recently reported strong third quarter results, with revenue and earnings surpassing analyst expectations and the company raising its full-year revenue and margin guidance. Key ...

PODD's Q3 earnings and revenues top forecasts, with strong Omnipod growth and margin expansion lifting shares.